Chest Medicine | Page 30 of 170 | Links Medicus Content Curation & Alerts in Medicine

Cohort Study: Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism.

3 May, 2022 | 10:41h | UTC

Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study – European Heart Journal

Commentary on Twitter

Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study https://t.co/IOvHAzKwa2 #EHJ #ESCYoung @ehj_ed @rladeiraslopes pic.twitter.com/ADFp09rooI

— European Society of Cardiology Journals (@ESC_Journals) May 2, 2022

ATS/ERS/JRS/ALAT Guideline: Idiopathic pulmonary fibrosis and progressive pulmonary fibrosis in adults.

2 May, 2022 | 00:53h | UTC

Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline – American Journal of Respiratory and Critical Care Medicine

Commentary on Twitter (thread – click for more)

🔥Finally out online: the latest multisocietal guidance defining progression in fibrotic lung disease🫁 has arrived!

These long-awaited guidelines help better clarify disease definition and guide treatmenthttps://t.co/LVuoVdZRj2

What does this mean? Hang on to your hats! 🧵1/n pic.twitter.com/3jvFGSfSuI

— Deji Adegunsoye, MD, PhD (@drdayjee) April 29, 2022

Pfizer says COVID treatment Paxlovid fails to prevent infection of household members.

2 May, 2022 | 00:43h | UTC

Pfizer says COVID treatment Paxlovid fails to prevent infection of household members – Reuters

Commentary on Twitter

Pfizer Inc on Friday said a large trial found that its COVID-19 oral antiviral treatment Paxlovid was not effective at preventing coronavirus infection in people living with someone who had been exposed to the virus. https://t.co/95zphEYaxc

— Reuters Health (@Reuters_Health) April 29, 2022

Review: Novel approaches to imaging the pulmonary vasculature and right heart.

2 May, 2022 | 00:29h | UTC

Novel Approaches to Imaging the Pulmonary Vasculature and Right Heart – Circulation Research (free for a limited period)

RCT: Effect of an interdisciplinary weight loss and lifestyle intervention on obstructive sleep apnea severity.

29 Apr, 2022 | 08:14h | UTC

Effect of an Interdisciplinary Weight Loss and Lifestyle Intervention on Obstructive Sleep Apnea Severity: The INTERAPNEA Randomized Clinical Trial – JAMA Network Open

Commentary: Weight Loss, Lifestyle Interventions Improve Obstructive Sleep Apnea – HCP Live

Commentary on Twitter

This RCT found a weight loss & lifestyle intervention for adults with CPAP-treated moderate-to-severe OSA resulted in sustained improvements in OSA severity & comorbidities and health-related quality of life; at 6 months, 62% no longer needed CPAP. https://t.co/5jmFJ8mnis

— JAMA Network Open (@JAMANetworkOpen) April 22, 2022

E-cigarettes and nicotine abstinence: a meta-analysis of randomized controlled trials.

29 Apr, 2022 | 08:08h | UTC

E-cigarettes and nicotine abstinence: a meta-analysis of randomised controlled trials – European Respiratory Review

Disease burden associated with alpha-1 antitrypsin deficiency: systematic and structured literature reviews.

29 Apr, 2022 | 08:09h | UTC

Disease burden associated with alpha-1 antitrypsin deficiency: systematic and structured literature reviews – European Respiratory Review

Development and validation of the symptom burden questionnaire for long covid (SBQ-LC): Rasch analysis.

28 Apr, 2022 | 10:56h | UTC

Development and validation of the symptom burden questionnaire for long covid (SBQ-LC): Rasch analysis – The BMJ

Commentary on Twitter

https://twitter.com/bmj_latest/status/1519430941759918080

Clinical Review: Diagnosis and management of covid-19 in pregnancy.

27 Apr, 2022 | 08:13h | UTC

Diagnosis and management of covid-19 in pregnancy – The BMJ

Review: The evolving clinical practice of chronic cough.

27 Apr, 2022 | 08:06h | UTC

The Evolving Clinical Practice of Chronic Cough – Mayo Clinic Proceedings

Rapid molecular tests for tuberculosis and tuberculosis drug resistance: a qualitative evidence synthesis of recipient and provider views.

27 Apr, 2022 | 07:52h | UTC

Rapid molecular tests for tuberculosis and tuberculosis drug resistance: a qualitative evidence synthesis of recipient and provider views – Cochrane Library

Summary: Rapid molecular tests for tuberculosis and tuberculosis drug resistance: the views and experiences of people who are tested and healthcare providers – Cochrane Library

Commentary: Molecular tests for TB: Global rollout of rapid molecular tests for tuberculosis over the last 12 years – Liverpool School of Tropical Medicine

Covid-19: Only a quarter of patients admitted to hospital feel fully recovered after a year, study finds.

26 Apr, 2022 | 08:45h | UTC

Covid-19: Only a quarter of patients admitted to hospital feel fully recovered after a year, study finds – The BMJ

Original Study: Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study – The Lancet Respiratory Medicine

Invited Commentary: Long COVID: systemic inflammation and obesity as therapeutic targets – The Lancet Respiratory Medicine

Commentary on Twitter (thread – click for more)

PHOSP-COVID study:
– 232 (29%) of 804 pts fully recovered at 1y
– Female sex, obesity, & IMV = less likely to feel fully recovered
– inflamm mediators📈in those w/ most severe physical, mental health, & cognitive impairments

Read it here: https://t.co/rVZuVDo4xl

— The Lancet Respiratory Medicine (@LancetRespirMed) April 25, 2022

Persistent COVID-19 symptoms in a community study of 606,434 people in England.

26 Apr, 2022 | 08:48h | UTC

Persistent COVID-19 symptoms in a community study of 606,434 people in England – Nature Communications

Commentary on Twitter

Thirty-eight percent of participants from a community-based study of symptoms following COVID-19 reported persistent symptoms that lasted 12 weeks or more, according to an article published in @NatureComms. https://t.co/sAEutdOkSS pic.twitter.com/oCyyXGIRbk

— Nature Portfolio (@NaturePortfolio) April 20, 2022

Yes, relapses after Paxlovid happen — now what?

26 Apr, 2022 | 08:18h | UTC

Yes, Relapses After Paxlovid Happen — Now What? – HIV and ID Observations

Commentary on Twitter

Some additional thoughts about relapsing Covid19 after treatment with Paxlovid.

Bottom line — *lots* of unknowns, starting w/ how often it happens.

Looking forward to @pfizer sharing further data on the relapsing cases from their EPIC-HR study. https://t.co/1MMhqn4elw

— Paul Sax (@PaulSaxMD) April 25, 2022

Echocardiography findings in COVID-19 patients admitted to intensive care units: a multi-national observational study.

25 Apr, 2022 | 01:00h | UTC

Echocardiography findings in COVID-19 patients admitted to intensive care units: a multi-national observational study (the ECHO-COVID study) – Intensive Care Medicine

Commentary on Twitter

Echocardiography in #COVID19 #ICU pts, ECHO-COVID study
♥︎ systolic dysfunction in ⅓: 23% LV (similar to septic cardiomyopathy), 22.5% RV (due to P overload)
♥︎ ACP in 17% (due to hypercapnia, PE, MV)
♥︎ ACP/age associated with in-ICU mortality
📖 https://t.co/NUlAZh9hHw pic.twitter.com/t17pNolFqy

— Intensive Care Medicine (@yourICM) April 21, 2022

RCT: Segmentectomy resulted in better outcomes than lobectomy in small-sized peripheral non-small-cell lung cancer.

25 Apr, 2022 | 01:03h | UTC

Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial – The Lancet (link to abstract – $ for full-text)

Point/Counterpoint: Should asymptomatic OSA be treated in patients with significant cardiovascular disease?

25 Apr, 2022 | 00:24h | UTC

POINT: Should Asymptomatic OSA Be Treated in Patients With Significant Cardiovascular Disease? Yes – CHEST

COUNTERPOINT: Should Asymptomatic OSA Be Treated in Patients With Significant Cardiovascular Disease? No – CHEST

WHO recommends highly successful COVID-19 therapy (nirmatrelvir-ritonavir) and calls for wide geographical distribution and transparency from originator.

22 Apr, 2022 | 09:36h | UTC

WHO recommends highly successful COVID-19 therapy and calls for wide geographical distribution and transparency from originator – World Health Organization

One-year follow-up of a RCT: In ICU patients with severe hypoxemia, there was no difference in long-term mortality and health-related quality of life with lower vs. higher oxygenation targets.

22 Apr, 2022 | 09:32h | UTC

Long-term mortality and health-related quality of life of lower versus higher oxygenation targets in ICU patients with severe hypoxaemia – Intensive Care Medicine

Original Study: Lower or Higher Oxygenation Targets for Acute Hypoxemic Respiratory Failure – New England Journal of Medicine

Commentary on Twitter

Lower (8 kPa) vs higher oxygenation (12 kPa) targets: no longterm survival benefit nor HRQoL improvement at 1y in #ICU pts with severe hypoxaemia (HOT-ICU trial cohort). Substantial impairments in several EQ-5D-5L dimensions in survivors in both groups.
🖇️ https://t.co/P48Cd5sIWK pic.twitter.com/JBFEIqDdcB

— Intensive Care Medicine (@yourICM) April 20, 2022

RCT: Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for prevention of Covid-19.

21 Apr, 2022 | 10:29h | UTC

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19 – New England Journal of Medicine

Commentary on Twitter

AZD7442 (tixagevimab/cilgavimab) found to have about 76% efficacy in preventing symptomatic Covid-19 infection. https://t.co/8tmvz3xI4I pic.twitter.com/fOegZjBRA6

— NEJM (@NEJM) April 20, 2022

Cohort study: COVID-19 infection granted patients strong and long-lasting protection from reinfection.

21 Apr, 2022 | 10:20h | UTC

News Release: COVID-19 infection granted patients strong and long-lasting protection from reinfection – Providence Health & Services

Original Study: Rates of COVID-19 Among Unvaccinated Adults With Prior COVID-19 – JAMA Network Open

Commentary: COVID-19 infection may offer similar immunity as vaccination – CIDRAP

Commentary on Twitter

This US cohort study found that unvaccinated individuals with prior symptomatic #COVID19 had 85% lower risk against recurrent COVID-19 compared to unvaccinated individuals without prior infection, for up to 9 months, through November, 2021. https://t.co/1qHCFmGqXG

— JAMA Network Open (@JAMANetworkOpen) April 20, 2022

Covid hasn’t given up all its secrets. Here are 6 mysteries experts hope to unravel.

20 Apr, 2022 | 09:57h | UTC

Covid hasn’t given up all its secrets. Here are 6 mysteries experts hope to unravel – STAT

A nonrandomized controlled study found awake prone position (median of 4.2 hours per day) may not benefit hospitalized adults with Covid-19.

20 Apr, 2022 | 09:56h | UTC

Assessment of Awake Prone Positioning in Hospitalized Adults With COVID-19: A Nonrandomized Controlled Trial – JAMA Internal Medicine

Commentaries:

Prone Positioning for Nonintubated Patients With COVID-19—Potential Dangers of Extrapolation and Intermediate Outcome Variables – JAMA Internal Medicine

Study suggests worse outcomes for awake COVID patients in prone position – CIDRAP

Putting Hospitalized COVID Patients on Their Belly May Not Be a Good Idea After All – HealthDay

Awake prone positioning for non-intubated patients with COVID-19-related acute hypoxaemic respiratory failure: a systematic review and meta-analysis – The Lancet Respiratory Medicine

Prone positioning of patients with moderate hypoxaemia due to covid-19: multicentre pragmatic randomised trial (COVID-PRONE) – The BMJ

RCT: Prone positioning of patients with moderate hypoxia due to COVID-19 – medRxiv

Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial – The Lancet Respiratory Medicine

Awake prone positioning in patients with hypoxemic respiratory failure due to COVID-19: the PROFLO multicenter randomized clinical trial – Critical Care

Prone Positioning of Nonintubated Patients With Coronavirus Disease 2019—A Systematic Review and Meta-Analysis – Critical Care Medicine

Commentary on Twitter (thread – click for more)

Important negative study: non randomized trial finds no clinical benefit to awake proning vs usual care in COVID

No difference in rates of intubation, length of stay, or 28 day mortality

Medicine is humbling. This emphasizes the importance of trials
📄https://t.co/ksh9Ic9XBL
1/ pic.twitter.com/sjHHv4WQs8

— Nick Mark MD (@nickmmark) April 18, 2022

M-A: Global prevalence of post COVID-19 condition or long COVID.

19 Apr, 2022 | 02:18h | UTC

Global Prevalence of Post COVID-19 Condition or Long COVID: A Meta-Analysis and Systematic Review – The Journal of Infectious Diseases

Commentary: Global data reveal half may have long COVID 4 months on – CIDRAP

Commentary on Twitter (thread – click for more)

🚨The so far largest meta-analysis of more than 1.5 million infected individuals puts the global prevalence of #LongCovid at 43%. Some additional key findings. 🧵https://t.co/XGu23MV3Ra
1/

— Jonas R. Kunst (@kunstjonas.bsky.social) (@KunstJonas) April 17, 2022

Review: Covid-19: virology, variants, and vaccines.

18 Apr, 2022 | 10:50h | UTC

Covid-19: virology, variants, and vaccines – BMJ Medicine

Commentary on Twitter

🆕 New review on #COVID: virology, variants and vaccines by Megan Young, Harry Crook, Janet Scott and Paul Edison from @ImperialMed
➡️ Read it now! https://t.co/hYrCQYVvNr #BMJMedicine #MedTwitter pic.twitter.com/aGA0DsX38K

— BMJMedicine (@BMJMedicine) April 14, 2022

Stay Updated in Your Specialty